<DOC>
	<DOCNO>NCT01154101</DOCNO>
	<brief_summary>This double-blind , placebo-controlled study conduct 5 study center United States . Approximately 30 subject moderate severe plaque-type psoriasis take part . The study consist screen period 21 day , 12-week treatment period 7 on-treatment clinic visit ( approximately one every 2 week ) post-dosing follow-up clinic visit approximately 30 day last dose study drug take . Subjects randomize receive either 250mg , 500mg 1000mg study drug placebo . Study drug take mouth full stomach , every day 84 day . Vital sign , clinical laboratory result ( hematology , chemistry , urinalysis ) , ECGs physical examination assess periodic interval Day 1 Day 84 . A skin biopsy take begin end dose period evaluate effect study drug psoriasis . Investigators perform psoriasis evaluation ( include Psoriasis Area Severity Index [ PASI ] Physician 's Global Assessment [ PGA ] 5 different time throughout study quantify effect SRT2104 psoriasis activity . Subjects complete questionnaire throughout study , document sense well-being mood 4 different time study . Five blood sample obtain different timepoints study , measure amount SRT2104 body .</brief_summary>
	<brief_title>Study Clinical Activity , Safety , Tolerability SRT2104 Subjects With Moderate Severe Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Able willing provide write informed consent participate study Be male female age 18 80 year ( inclusive ) Have diagnosis clinically confirm , stable ( without recent document flare within 30 day prior Screening Visit ) , plaquetype psoriasis least 6 month involve ≥10 % body surface area Have baseline PASI ≥10 Be candidate systemic psoriasis therapy , opinion investigator If female subject childbearing potential , willing use reliable contraception duration study , 30 day safety follow telephone call Be willing able comply protocol duration study Has receive systemic nonbiologic psoriasis therapy PUVA phototherapy within 4 week prior Screening Visit , topical psoriasis treatment UVB phototherapy within 2 week prior Screening Visit Has receive previous treatment biologic agent within 5 drug halflives ( within 3 month halflife unknown ) prior first dose SRT2104 Has receive live vaccination within 4 week prior Screening Visit intend live vaccination course study Use nonpsoriatic prescription drug therapy , exception prescription medication administer stable dose least 6 week prior Screening Visit ; however , administration proton pump inhibitor study dose period prohibit Use dietary herbal supplement , exception administer stable dose least 6 week prior Screening Visit Has receive investigational drug experimental procedure within 30 day prior first dose SRT2104 Has active infection ( e.g. , sepsis , pneumonia , abscess , etc . ) high risk develop infection , opinion investigator , prior first dose SRT2104 Has history positive tuberculosis test positive tuberculosis test Screening Visit attribute prior BCG inoculation Has positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening Visit Has positive test HIV antibody Has abnormal chest xray Screening Visit , opinion investigator , would preclude entry trial Has 12lead electrocardiogram ( ECG ) change consider clinically significant medical review include prolonged QTc interval define : QTcB ≥450 msec ( base single average QTc value triplicate ECGs obtain brief period ) QTcB ≥480 msec subject Bundle Branch Block Has renal liver impairment , define : Serum creatinine level ≥ 1.4 mg/dL female ≥ 1.5 mg/dL male AST ALT ≥ 2xULN Alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Has active neoplastic disease history neoplastic disease within 5 year study entry ( except basal squamous cell carcinoma skin , carcinoma situ definitively treat standard care approach ) Is pregnant breastfeeding . Confirmation female subject pregnant must establish negative pregnancy test Screening Day 1 Has significant history alcoholism drug/chemical abuse , consume 3 standard units/day alcohol . A standard unit alcohol define 250 mL beer , 25 mL spirit , 125 mL wine History sensitivity study medication , component thereof , history drug allergy , opinion investigator medical monitor , contraindicate participation Has acute chronic illness , opinion investigator , could pose threat harm subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>